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Abstract 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is one of the most common causes of sudden 
cardiac death in young people. Patients diagnosed with ARVC may experience increased likelihood of 
development of anxiety and depression, emphasizing the need for accurate diagnosis. To assist future 
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genetic diagnosis and avoidance of misdiagnosis, we evaluated the reported monogenic disease-causing 
variants in ARVD/C Genetic Variants Database, Human Gene Mutation Database, and ClinVar.  
Within the aforementioned databases, 630 monogenic disease-causing variants from 18 genes were 
identified. In the genome Aggregation Database, 226 of these were identified; 68 of which were found at 
greater than expected prevalence. Furthermore, 37/226 genetic variants were identified amongst the 
409,000 UK biobank participants, 23 were not associated with ARVC. Among the 14 remaining variants, 13 
were previously found with greater than expected prevalence for a monogenic variant. Nevertheless, they 
were associated with serious cardiac phenotypes, suggesting that these 13 variants may be disease-
modifiers of ARVC, rather than monogenic disease-causing. In summary, more than 10% of variants 
previously reported to cause ARVC were found unlikely to be associated with highly penetrant monogenic 
forms of ARVC. Notably, all variants in OBSCN and MYBPC3 were found, making these unlikely to be 
monogenic causes of ARVC. 
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Arrhythmogenic right ventricular cardiomyopathy, gnomAD, Cardiac Proteomics, Genetic Variants, 
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Introduction 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inheritable cardiac muscle disorder, in which 
the myocardium is progressively replaced by fibrofatty tissue. Prevalence of the disease varies within 
regions, though in some areas is estimated to be responsible for as many as 20% of all cases of sudden 
cardiac death among people under 35 years of age1.  The disease primarily involves the right ventricle, 
although left ventricular involvement occurs and in some cases predominates2. Additionally, exercise is 
known to accelerate the onset and/or progression of ARVC1. This emphasizes the need for early diagnosis 
and risk assessment of ARVC, particularly as life-threatening arrhythmias often occur during the concealed 
phase of the disease3. Unfortunately, early diagnosis of ARVC is particularly difficult.  Current task force 
criteria4 are used as standards for disease diagnosis and include genetic testing. However, as with other 
inheritable diseases, discerning the significance of genetic variants is particularly challenging. To assist in 
this challenge, we have intersected multiple publicly available databases to help critically evaluate the 
previously reported disease-causing genetic variants.   
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The genome Aggregation Database5 (gnomAD r2.1.1) contains 123,136 unrelated exome sequences that 
are used to represent the general population in this study, hence do we expect occurrence of ARVC-causing 
genetic variants in this database (http://gnomad.broadinstitute.org/). gnomAD is the largest publicly 
available population data set, and the populations have been sub-grouped based on principal component 
analysis. This database may be used to evaluate the prevalence of genetic variants reported to cause ARVC 
in the general population and thus its likelihood of causing the disease. However, the gnomAD database 
lacks phenotype data. Thus, as an additional step we compared the identified disease-causing variants from 
gnomAD against PheWeb6 (http://pheweb.sph.umich.edu:5003/), a phenome-wide association study based 
on 409,000 UK biobank participants. Finally, we integrated high-resolution proteomics data from each of 
the cardiac chambers of Sus scrofa hearts (n=3) in order to further support our categorization and 
evaluation of genes and their variants. These multi-step intersecting analyses allowed us to reduce the 
number of variants – and the number of genes - likely to be related to the disease. We propose that a 
continuous refinement through additional databases as they become available can serve as an added tool 
for diagnosis and assessment of risk in ARVC-affected population.  
Methods 
Databases searched for reportedly monogenic disease-causing variants 
We evaluated pathogenic and likely pathogenic small deletions related to ARVC reported in the Human 
Gene Mutation Database7 (www.hgmd.cf.ac.uk - HGMD Professional 2017.4, visited March 2018), ClinVar8 
(https://www.ncbi.nlm.nih.gov/clinvar/ - visited March 2018)  and in the ARVD/C Genetic Variants 
Database9 (update from February 2015, visited March 2018 - https://molgenis136.gcc.rug.nl/). The variants 
in HGMD were queried using the phenotype: “arrythmogenic right ventricular cardiomyopathy” and 
“cardiomyopathy, arrhythmogenic right ventricular”. ClinVar variants were identified by searching: “ARVC” 
OR "arrhythmogenic right ventricular"”. Variants were only included if they were pathogenic/likely 
pathogenic and had the phenotype “ARVC” or “arrhythmogenic right ventricular”. Only ClinVar variants 
with multiple non-conflicting submitters or originating from: “research” or “literature only” were included. 
JUP and DSP variants reported to be recessively inherited in any database were removed. 
Variant prevalence analysis in gnomAD 
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The reportedly monogenic disease-causing variants were searched for in the 123,136 exomes in gnomAD 
(r2.1.1)5. Each gene’s association to ARVC was ranked based on the amount of variants within it not found 
in gnomAD. Variants were only included if they had gnomAD filter status of “PASS”, meaning the variant 
passed all gnomAD quality control filtering. Genotype prevalence was calculated based on the allele count, 
the amount of homozygous people with the variant, and coverage at the allele location. According to 
American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology 
(AMP) guidelines for variant interpretation,10 variant prevalence above disease prevalence is recognized as 
strong evidence for a variant being benign, regardless of its over-representation being in the general 
population or only in a subpopulation (ethnic group). Based on disease prevalence, a genotype prevalence 
above 1:2000 was considered greater than expected and was used as a cutoff for each individual variant. 
Using this data set, we can evaluate the prevalence of the reported ARVC variants.  Additionally, all variants 
were scored using the Combined Annotation Dependent Depletion (CADD) scoring system to in-silico predict 
the deleteriousness of the ARVC variants11.  Furthermore, we evaluated the number of variants found to be 
prevalent in the general population (in gnomAD) against the number of variants reported in each of the 
databases reporting ARVC-related variants.   
Phenome-wide association study data from 409,000 participants in UK biobank 
To support the prevalence analysis, phenotype evidence from PheWeb12 
(http://pheweb.sph.umich.edu:5003/ - visited May 2018) was used. PheWeb is a phenome-wide 
association study conducted on the 409,000 Caucasian UK biobank participants. The following phenotypes 
were considered an indicator that the variant could predispose for ARVC: Any cardiomyopathy, “Heart 
Failure,” “Ventricular fibrillation,” “myocarditis,” “paroxysmal ventricular tachycardia,” and “Cardiac 
arrest.” A variant was also considered potentially predisposing for ARVC, if it displayed significant 
association with another pathogenic phenotype from the circulatory system after correction for multiple 
hypothesis testing.    
Proteomics analysis of protein abundance in cardiac chambers  
We used data from proteomics experiments of each of the four cardiac chambers, which were obtained 
from three adult pigs (Sus scrofa) (personal communication, Associate professor A. Lundby). Sample 
processing was performed in a similar way as recently published by Linscheid et al13. Briefly, cardiac tissue 
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biopsies were collected and immediately snap frozen in liquid NO2 and stored (–80 °C). Protein extraction of 
biopsies (2 mg per sample) was followed by digestion as described previously 14,15.  Desalted digested 
peptides were fractionated into 12 fractions by micro-flow reverse-phase ultrahigh pressure liquid 
chromatography. Following this, samples were separated on 15 cm fused-silica emitter columns (in a 1 h 
multi-step linear gradient). These were analyzed by online reversed-phase liquid chromatography coupled 
to a Q-Exactive Plus quadrupole Orbitrap tandem MS. Using the MaxQuant software, we processed the raw 
MS data. To identify proteins, we used a built-in Andromeda search engine containing human SwissProt 
protein entries. From these experiments, in total we measured 7206 proteins. Rank analysis was based on 
summed MS-based protein intensities. Protein abundance ratios between cardiac chambers were 
investigated by examining the median log2 fold change difference between cardiac chambers from each 
pig. To investigate the relative abundance of proteins encoded by ARVC associated genes, proteins were 
ranked and plotted according to abundance using the median protein intensities from the right ventricle 
after iBAQ correction.   
Results 
Variants Identified in gnomAD 
To evaluate variants that are reported to cause ARVC, we gathered variants claimed pathogenic or likely 
pathogenic in either ARVC-database16, ClinVar8, and HGMD7. A total of 630 unique genetic variants from 18 
different genes reported ARVC-causing were identified, which can be found in supplementary file 1. The 
630 disease associated variants were found across 18 different genes (PKP2, DSP, DSG2, DSC2, LMNA, DES, 
JUP, RYR2, TTN, SCN5A, PLN, CTNNA3, CDH2, TMEM43, OBSCN, MYBPC3, and DMD). A combined 87% of 
the genetic variants were found within the top 5 genes, PKP2, DSP, DSG2, DSC2, and JUP. In contrast, across 
the bottom 8 genes only 3% variants were identified (Table 1). The protein expression pattern between 
atria and ventricles were then examined (Figure 1). The five most common desmosomal genes have a 
general trend towards being expressed more highly within the ventricles (Figure 1a) and a small trend 
towards the right ventricle (Figure 1c). Meanwhile, the general trend of the remaining ARVC-associated 
genes is towards the atria (Figure 1b). Furthermore, to ensure that this discrepancy in expression pattern 
was not due to very low expression in one chamber, we plotted a rank plot of abundance levels within the 
right ventricle of the 18 genes. All except one protein were detected with above median intensity within 
the right ventricle. High expression does not exclude the variant from being benign, despite MYBPC3 being 
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in the 95-percentile of protein expression within the ventricle, it is still expressed more so in the atria of the 
pig. Therefore, it is important to evaluate based on relative expression pattern and not absolute expression 
within a heart chamber. Using this information together with the number of variants within each gene 
identified within gnomAD, we categorize the genes depending on the confidence that the genes are indeed 
associated with ARVC (Table 1). From these 18 genes, the 630 genetic variants were next evaluated through 
their prevalence in the general population, and the phenotypes each variant is associated with. 
Sixty seven variants with prevalence evidence for inaccurate variant interpretation 
From the total list of 630 unique genetic variants claimed to cause ARVC, 226 variants were found in the 
general population database, gnomAD. Identification of a genetic variant in gnomAD does not by itself 
preclude pathogenicity. According to ACMG and AMP guidelines10 pathogenic variants with prevalence 
greater than the disease prevalence (genotype prevalence > 1:2000) in gnomAD is considered strong 
evidence for a variant being benign. From the 226 variants identified in gnomAD, 68 genetic variants were 
present at a frequency incompatible with causation of penetrant variants. Each of the 68 variants were 
found with prevalence above our conservative cutoff of 1:2000, in one or more subpopulation(s) of 
gnomAD. gnomAD’s subpopulations are subsetted based on different population ethnicities (eg. African, 
Non-Finnish European, south Asian etc.).  Furthermore, 36/68 variants had a prevalence above 1:2000 in 
the overall population in gnomAD, meaning each of these 36 variants should in theory alone account for all 
the expected the ARVC individuals within gnomAD. Therefore, these 68 variants reported to be monogenic 
causes of ARVC have strong evidence for being benign and thus for currently being inaccurately 
interpreted. All 630 variants were assessed in silico using a meta-score prediction tool, CADD11. CADD 
scores of the variants identified in gnomAD were compared to those not found using student’s t-test, which 
resulted in a p-value 6.35e-8, indicating there was a significant difference in CADD scores between variants 
found in gnomAD, and those not found, supporting our gnomAD findings. When diving into these CADD 
scores we saw that the percentage of variants that scored in the top 0.1% most deleterious variants 
dropped considerably between variants not found in gnomAD (50.56%), those found in gnomAD with low 
prevalence (22.22%), and those found in gnomAD at prevalence incompatible with monogenic disease-
causing variants (7.5%) (see figure 2).  
Twenty four variants not found significantly associated to serious cardiac phenotypes. 
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Following the evaluation of variant frequency, the phenotype associated with the genetic variants found in 
gnomAD were investigated via query in the PheWeb database. In PheWeb, 37 variants out of the 226 
variants identified in gnomAD were identified. Out of these 37 variants, all but two variants (35) had 
previously been found to have a frequency incompatible with pathogenic variants in gnomAD, which 
indicated these 35 were benign. In PheWeb, 23 of these 37 variants showed no sign of being associated 
with any ARVC-like phenotypes supporting their evaluation based on their genotype prevalence (see table 
2). However, 14 variants showed an association with ARVC-like phenotypes (nominal 𝑝 < 0.05), but only 
one was significant after correcting for multiple statistical testing. All associated ARVC-like phenotypes 
display large odds-ratios, indicating they have strong association to their phenotype(s). One variant 
(rs201856473) was of low prevalence (Genotype prevalence = 0.00013) in the gnomAD database and 
displayed association to ARVC-related phenotypes in UK biobank, indicating it is likely disease predisposing. 
Of the remaining 23 variants that did not display association to ARVC-related phenotypes in UK Biobank, 22 
had previously been found with greater than expected prevalence in gnomAD. The single aforementioned 
variant (rs201564919) with gnomAD prevalence below our cutoff was found in PheWeb to show no 
association to serious cardiac phenotypes, which is considered strong evidence for benignity. Adding the 
single variant with gnomAD prevalence below our threshold that displayed no signs of being associated to 
ARVC in PheWeb, brings the total variants with evidence of being inaccurately classified to 69. However, 13 
variants were found to be associated with serious cardiac phenotypes, conflicting with their evidence for 
benignity from the prevalence analysis.  
ARVD/C Genetic Variants Database is the preferred database according to gnomAD analysis 
Of the three databases the variants are sourced from, HGMD displays the highest number of variants 
detected in gnomAD. ClinVar and the ARVC-database contained a similar percentage of variants also found 
at high levels in gnomAD; however, the ARVC-database includes more variants than the other databases (by 
a factor of 4) and as such, showed the best performance in terms of total number of variants reported after 
excluding those of high prevalence in the general population (see figure S1).  
Discussion  
Thirteen inaccurately classified ARVC variants predispose for other serious cardiac phenotypes  
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Over 1/3 of the monogenic disease-causing variants were identified within gnomAD (226/630), which is in 
agreement with a previous study by Hall et al, which focused only on variants from the ARVC database, 
identifying 117 out of 364 pathogenic variants17. The 226 variants with questionable ARVC association were 
evaluated using phenome-wide association study data from UK biobank (PheWeb). A total of 37 of these 
variants were found within the UK biobank data set. Approximately two thirds of these variants (23/37) 
were not associated with any phenotypes that may associate to ARVC, thus suggesting that they are not 
pathogenic (Table 2). The remaining 14 variants appeared to predispose to cardiac phenotypes. The variant 
with the lowest p-value association to its phenotype was variant rs147240502 (p = 0.000012), however, the 
reported association in PheWeb was to the term “aortic aneurysm”, a phenotype not directly related to 
ARVC. Interestingly, 13/14 variants were found associated with one or more serious cardiac phenotype(s) in 
PheWeb, despite displaying greater than expected prevalence in the overall gnomAD population. 
Additionally, it is noteworthy that 11 of these variants were found with odds-ratios above 5 (see table 2). 
We therefore propose that these 13 variants are previously unreported disease modifiers of ARVC, as they 
are unlikely to be monogenic disease-causes of ARVC.  
Challenging three entire genes of their association to ARVC as sources of monogenic pathogenic variants 
One fourth (68/226) of the variants found in gnomAD displayed a genotype prevalence above cutoff in the 
overall gnomAD population, or in one of its subpopulations, thus challenging their current status as 
monogenic disease-causing variants.  It is important to note that these 68 variants are found at a rate 
incompatible with monogenic disease-causing variants of ARVC. This does not exclude the variants from 
being disease-causing of other diseases. They are only classified as highly unlikely to be monogenic disease 
causing of ARVC. Furthermore, we identified three genes (OBSCN, MYBPC3, and DMD) to be “low 
confidence” genes (Table 1) given that all the variants within these genes were found in gnomAD and due 
to their relative low expression pattern in the ventricles compared to atria (Figure 1). We expect the 
protein expression to trend towards being higher in the RV, since variants within these genes are reported 
to cause ARVC, which manifests itself primarily in the right ventricle. However, most of the medium and 
low-confidence genes are expressed more so in the atria. The percentage of variants found in gnomAD 
within the genes and their protein expression allows us to question the actual association of the three 
bottom genes (OBSCN, MYPBC3, and DMD) to ARVC. Not only did OBSCN and MYBPC3 have all their 
variants identified in gnomAD, their two variants were both identified at an occurrence incompatible with 
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disease-causing variants.  From the results of our study, we propose that these three genes ought to be 
evaluated further, to conclusively determine if variants within them are able to cause ARVC. Note that for 
JUP, a desmosomal protein, 19/24 of its variants identified in gnomAD and 2 of these had a high 
prevalence. Recessive JUP mutations have been associated to the recessive genetics disease, Naxos disease, 
a cardiocutaneous syndrome which may complicate interpretation if this was not reported clearly in the 
original publications.  
Monogenic disease-causing variants’ genotype prevalence highly unlikely to exceed 1:2000  
Our analysis retrospectively examines variants that were associated to patients with the diagnosis of ARVC.  
With our study, we seek to improve the clarity of interpretation of variants reported during genetic testing. 
We have intersected existing databases as a mean of exploring the likelihood of a reported variant in ARVC-
related databases to be causative of disease. We used the prevalence of 1:2000 as the cutoff value in 
gnomAD. This is a very conservative approach, since even variants in the most common gene (PKP2) are 
only found in 10-45% of patients3. We based this cutoff on the disease prevalence in people of european 
descent, which is the largest subpopulation in gnomAD 5. We reasoned that if the variant is disease-causing, 
then the disease prevalence should at least match the occurrence of the variant.  By using a 1:2000 (rather 
than a 1:5000) cutoff, we conservatively estimated the likelihood of a variant being benign and not linked 
to disease. Our study also found that genes OBSCN, MYBPC3, and DMD are unlikely to be causative of the 
ARVC phenotype. Especially OBSCN given that the variant reported in these genes are prevalent above 
1:2000 in the overall population of gnomAD.  
Identification of Potential Disease-modifying Genetic Variants 
Our analytical methods were able to identify potential a substantial number of non-monogenic disease-
causing genetic variants. Interestingly, some of these down-classified variants seem to act as disease-
modifiers. For example, the variant with the second strongest association to its phenotype “(Other 
cardiomyopathies”) is DSG2 variant rs372174546. This variant also exhibits a very large odds-ratio, and its 
CADD score tells us that it is among the top 10% most deleterious variants. Yet, this variant has been found 
to have a prevalence greater than expected, although the location does not have the greatest coverage 
(~25,000 allele reads), it is present in 3 times the expected amount in non-Finnish-Europeans. The greater 
than expected prevalence suggests that this variant is not a monogenic disease-causing variant, instead we 
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propose that this variant is a disease-modifier. On the other hand, the DSC2 variant rs201856473 had a low 
in silico prediction score, indicating it could be a benign variant, yet it was found with the strongest 
association to its phenotype (“ventricular fibrillation and flutter”) of tested variants with odds-ratios 
greater than 5. This variant was also found with prevalence below our threshold in gnomAD. These two 
examples emphasizes the importance of the clinical presentation of ARVC within the family, as well as other 
criteria, well established by the Task Force4 need to be taken into account before a diagnosis and risk 
stratification is established.  
The single variant from OBSCN, rs200362121, was found in greater than expected frequency, however, it 
was also found with association to “cardiomyopathies” in Pheweb. We propose this OBSCN variant could be 
a disease modifier rather than a monogenic disease-causing variant. The single variant from MYBPC3 
(rs771143409) is identified in gnomAD in a frequency incompatible with monogenic disease-causing 
variants. Thus, OBSCN and MYBPC3 has their association to ARVC questioned, leaving very limited evidence 
that the gene is disease causing gene for ARVC.  
Limitations 
The ACMG and AMP standards 10 are subject to potential bias due to categorization depending on 
individual assessments. We have not assessed whether one or more disease-causing variant subside within 
each individual.  Our study performed substantial computer prediction on variants from three separate 
databases, thus we did not take experimental data into account. Please see original references to view 
these data. We cannot rule out that some variants could increase susceptibility of ARVC under certain 
circumstances such as strenuous exercise, which has been shown to de-mask potential disease-causing 
variants18.  
Genetic screening may assist identification of patients and family members, meaning misclassified genetic 
variants in patients may lead to erroneous risk stratification or misdiagnosis. This could have serious clinical 
consequences, emphasizing the importance of variants being reported causative being truly disease-
causing.  
Conclusion 
We have identified many variants previously considered monogenic causes of ARVC, and >25% were found 
in a large general population exome database. Furthermore,  more than 10% of the genetic variants were 
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found at a prevalence incompatible with disease causing variants according to American College of Medical 
Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) variant interpretation 
guidelines10. Included in these 10% were all variants reported from OBSCN and MYBPC3 indicating that 
these genes do not need to be sequenced when attempting to identify the causal genetic variant. 
Interestingly, a focused analysis using over 400,000 UK biobank participants suggests that 13 genetic 
variants play a disease-modifying role rather than a monogenic disease-causing role for ARVC. We 
therefore, advise caution when incorporating genetic tools in the diagnosis of ARVC. 
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 Figure Legends: 
Figure 1: High resolution mass spectroscopy based cardiac proteomics data for ARVC genes – Protein 
abundance ratios for proteins encoded by ARVC genes is evaluated across cardiac chambers for 
(A+B) atria versus ventricles and for (C) right versus left ventricle. (D) The relative abundance in the 
right ventricle of proteins encoded by ARVC genes is shown as a rank-plot of iBAQ corrected MS 
intensities. Data points are based on cardiac biopsies from Sus scrofa (n=3). 
Figure 2:  ARVC associated genetic variants separated into ‘likely disease-causing’ (ARVC associated variants 
not found in gnomAD), ‘Questioned as monogenic disease-causing’ (ARVC associated variants found 
in gnomAD with prevalence below 1:2000), and ‘highly unlikely monogenic disease causing’ (ARVC 
variants found in gnomAD with prevalence above 1:2000). Shown in orange are variants CADD 
scored to be in the top 0.1% most deleterious variants. Shown in blue are variants below this 
threshold. 
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PKP2 230 57 173 
DSP 164 56 108 
DSG2 77 33 44 
DSC2 59 29 30 
LMNA 19 2 17 
DES 14 1 13 
JUP 18 18 0 
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RYR2 9 6 3 
TTN 11 8 3 
SCN5A 4 1 3 
PLN 4 1 3 
CTNNA3 3 0 3 
CDH2 2 0 2 
TMEM43 11 10 1 
TGFB3 2 1 1 
Lo
w
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OBSCN 1 1 0 
MYBPC3 1 1 0 
DMD 1 1 0 
 
Total 630 226 404 
 
Table 1 – Summary of genetic variants reported to be associated with ARVC. The number of variants 
identified within individual genes associated with ARVC are listed. In addition we summarize the number of 
these variants also found within the gnomAD database. The association to ARVC for variants summarized in 
“# Variants also in gnomAD” are dubious as to whether they are monogenic causes of ARVC. The genes are 
sorted into three confidence categories, high, medium, and low, based on the number of remaining ARVC 
variants. 
Gene rsID PheWeb AC P-value Beta Odds-ratio Phenotype 
LMNA rs142000963 2009 
    
OBSCN rs200362121 653 0.027 1.6 5.0 
Primary/intrinsic 
cardiomyopathies 
TTN rs72629793 219 
    
TTN rs72646853 64 0.03 9.0 >5 Cardiac arrest 
TTN rs72650011 2174 
    
TMEM43 rs35028636 135 0.021 0.8 2.2 
Congestive heart failure: 
nonhypertensive 
TMEM43 rs145619906 1297 
    
TMEM43 rs201916031 619 0.025 1.7 >5 
Primary/intrinsic 
cardiomyopathies 
TMEM43 rs139590716 69 
    
TMEM43 rs113449357 11699 
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DSP rs121912998 764 
    
DSP rs200473206 119 0.001 3.9 >5 Heart failure NOS 
DSP rs147315869 25 0.03 17.0 >5 Congestive heart failure? 
DSP rs28763961 130 
    
DSP rs148147581 258 
    
DSP rs150339369 182 
    
DSP rs142494121 133 
    
DSP rs141508330 142 
    
DSP rs138907450 166 0.037 1.9 >5 Congestive heart failure 
DSP rs28763967 14312 0.011 1.9 >5 Other Cardiomyopathies 
DSP rs147415451 259 
    
DSP rs116888866 148 
    
DSP rs11558732 7532 
    
PKP2 rs139734328 536 0.022 12.0 >5 Other Cardiomyopathies 
PKP2 rs146102241 3813 
    
PKP2 rs147240502 3221 
   
Other 
PKP2 rs200586695 123 
    
PKP2 rs143900944 23 
    
PKP2 rs139139859 1219 
    
PKP2 rs150821281 3508 
    
DSC2 rs147109895 777 0.01 2.0 >5 Cardiac arrest 
DSC2 rs201856473 227 0.00031 15.0 >5 
Ventricular fibrilation and 
flutter 
DSC2 rs144799937 938 
    
DSG2 rs372174546 410 0.0005 40.0 >5 Other Cardiomyopathies 
DSG2 rs191564916 728 
    
DSG2 rs139326669 111 
    
DSG2 rs201564919 59 
     
Table 2 - Evaluation of questionized ARVC variants in the phenome-wide association study of 409,000 
participants in UK biobank. Questionized variants associated with ARVC, but also found in gnomAD, 
were evaluated using data from 409,000 participants in UK biobank using the PheWeb resource6. For 
relevant cardiovascular phenotypes, any cardiomyopathy, heart failure, ventricular fibrillation, or cardiac 
arrest, their p-value and odds-ratio were included. 
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